Leading Circular RNA Therapeutics.
|
|
CircRNA Production Platform
————————
CirCode's proprietary circularization technology is based on the self-splicing activity of Group II intron ribozymes, allowing highly efficient circularization of any RNA in vitro. This technology features no scar sequence and low requirement, making it a robust and scalable option for industrial production.
Build on our circularization technology, CirCode has revolutionized the entire process of circular RNA production, achieving high effeiency, large scale with low cost.
Sequence Design Platform
———————
Unlike linear mRNA, the translation of circRNA is initiated through the translation initiation elements in a cap-independent manner. The translation of circRNA is typically less efficient than mRNA. However, its translation is cell- or tissue-specific.
CirCode has developed a high-throughput circRNA-based screening system that efficiently screens translation initiation elements. With millions of sequences already screened, we have obtained a large number of translation initiation elements, providing excellent translation efficiency. Furthermore, an AI-based sequence design program has been established specifically for circRNA. This program generates circRNA sequences routinely with amino acid sequences, with amazing translation efficiency.
Publication
———
Room 901, No.8,Jiafeng Road
Pudong New District,Shanghai
———
Address
Cooperation and media, please contact
info@circodebio.com
————
Contact Us
——————————————————————————————————————————————